Merck reported another Phase 3 success for sacituzumab, with a pivotal study in gastric cancer reaching its primary objectives. The result adds incremental momentum for Merck’s antibody-drug conjugate franchise as investors monitor the commercial ramp and the company’s broader patent-expiration risk. The release signals continued expansion beyond breast and urothelial indications, with the company positioning sacituzumab-based regimens for earlier lines or additional molecularly unselected populations depending on final protocol details. Overall, the update reinforces ADC execution as Merck’s near-term value-driver theme while it prepares for strategic portfolio shifts over the next several years.